254 related articles for article (PubMed ID: 19620209)
1. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
[TBL] [Abstract][Full Text] [Related]
2. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
Lindgren P; Geborek P; Kobelt G
Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
van den Hout WB; Goekoop-Ruiterman YP; Allaart CF; de Vries-Bouwstra JK; Hazes JM; Kerstens PJ; van Zeben D; Hulsmans HM; de Jonge-Bok JM; de Sonnaville PB; Dijkmans BA; Breedveld FC
Arthritis Rheum; 2009 Mar; 61(3):291-9. PubMed ID: 19248130
[TBL] [Abstract][Full Text] [Related]
4. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
5. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands.
Welsing PM; Severens JL; Hartman M; van Riel PL; Laan RF
Arthritis Rheum; 2004 Dec; 51(6):964-73. PubMed ID: 15593319
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment.
Laas K; Peltomaa R; Kautiainen H; Puolakka K; Leirisalo-Repo M
Ann Rheum Dis; 2006 Jul; 65(7):924-8. PubMed ID: 16339293
[TBL] [Abstract][Full Text] [Related]
7. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
8. Not all "quality-adjusted life years" are equal.
Marra CA; Marion SA; Guh DP; Najafzadeh M; Wolfe F; Esdaile JM; Clarke AE; Gignac MA; Anis AH
J Clin Epidemiol; 2007 Jun; 60(6):616-24. PubMed ID: 17493521
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice.
Virkki LM; Konttinen YT; Peltomaa R; Suontama K; Saario R; Immonen K; Jäntti J; Tuomiranta T; Nykänen P; Hämeenkorpi R; Heikkilä S; Isomäki P; Nordström D
Clin Exp Rheumatol; 2008; 26(6):1059-66. PubMed ID: 19210870
[TBL] [Abstract][Full Text] [Related]
11. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis.
Kobelt G; Lindgren P; Lindroth Y; Jacobson L; Eberhardt K
Rheumatology (Oxford); 2005 Sep; 44(9):1169-75. PubMed ID: 15956093
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of the determination of autoantibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis.
Konnopka A; Conrad K; Baerwald C; König HH
Ann Rheum Dis; 2008 Oct; 67(10):1399-405. PubMed ID: 18192304
[TBL] [Abstract][Full Text] [Related]
13. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective.
Jois RN; Leeder J; Gibb A; Gaffney K; Macgregor A; Somerville M; Scott DG
Rheumatology (Oxford); 2006 Dec; 45(12):1566-9. PubMed ID: 16705043
[TBL] [Abstract][Full Text] [Related]
14. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
15. Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis.
van den Hout WB; de Jong Z; Munneke M; Hazes JM; Breedveld FC; Vliet Vlieland TP
Arthritis Rheum; 2005 Feb; 53(1):39-47. PubMed ID: 15696568
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
[TBL] [Abstract][Full Text] [Related]
17. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
Kobelt G; Eberhardt K; Geborek P
Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
[TBL] [Abstract][Full Text] [Related]
18. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project).
Hallert E; Husberg M; Skogh T
Rheumatology (Oxford); 2006 Mar; 45(3):325-31. PubMed ID: 16287927
[TBL] [Abstract][Full Text] [Related]
19. Trends in economic consequences of rheumatoid arthritis over two subsequent years.
Verstappen SM; Jacobs JW; Kruize AA; Ehrlich JC; van Albada-Kuipers GA; Verkleij H; Buskens E; Bijlsma JW
Rheumatology (Oxford); 2007 Jun; 46(6):968-74. PubMed ID: 17337750
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada.
Kobelt G; Andlin-Sobocki P; Maksymowych WP
J Rheumatol; 2006 Apr; 33(4):732-40. PubMed ID: 16583476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
